A phase I trial of the dual kinase inhibitor GW572016 [lapatinib] in combination with topotecan in patients with advanced solid malignancies.
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2011
At a glance
- Drugs Lapatinib; Topotecan
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 26 May 2009 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
- 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2006 New trial record.